The use of glycopeptides is not without risk. Overuse and misuse can lead to the development of glycopeptide-resistant enterococci (GRE) and vancomycin-resistant Staphylococcus aureus (VRSA). These resistant strains complicate treatment protocols and require alternative therapeutic strategies, which may be less effective and more toxic. Monitoring resistance patterns is therefore a key aspect of epidemiological surveillance.
